Diagnosis and Treatment of Metabolic Acidosis in Patients with Chronic Kidney Disease - Position Statement of the Working Group of the Polish Society of Nephrology.
Adamczak, Marcin; Masajtis-Zagajewska, Anna; Mazanowska, Oktawia; Madziarska, Katarzyna; Stompór, Tomasz; Wiecek, Andrzej.
Kidney Blood Press Res
; 43(3): 959-969, 2018.
Artigo em Inglês | MEDLINE | ID: mdl-29895022
Leczenie kwasicy w przewleklej chorobie nerek.
Veverimer versus placebo in patients with metabolic acidosis associated with chronic kidney disease: a multicentre, randomised, double-blind, controlled, phase 3 trial.
Bicarbonate Therapy in End-Stage Renal Disease: Current Practice Trends and Implications.
Differential effects of phosphate binders on pre-dialysis serum bicarbonate in end-stage kidney disease patients on maintenance haemodialysis.
Oral treatment of metabolic acidosis in hemodialyzed patients and the implications on the hemodynamic status.
Oral Bicarbonate Slows Decline of Residual Renal Function in Peritoneal Dialysis Patients.
Long-term safety and efficacy of veverimer in patients with metabolic acidosis in chronic kidney disease: a multicentre, randomised, blinded, placebo-controlled, 40-week extension.
Current status of bicarbonate in CKD.
Correction of metabolic acidosis improves insulin resistance in chronic kidney disease.
Consequences and therapy of the metabolic acidosis of chronic kidney disease.